Neurocrine Biosciences Inc. (NASDAQ:NBIX) shares were down 1.5% during mid-day trading on Friday . The stock traded as low as $49.23 and last traded at $49.37, with a volume of 186,184 shares. The stock had previously closed at $50.12.

Several research analysts have issued reports on NBIX shares. HC Wainwright reaffirmed a “buy” rating on shares of Neurocrine Biosciences in a report on Friday, August 5th. Cowen and Company reaffirmed a “buy” rating and issued a $65.00 target price on shares of Neurocrine Biosciences in a report on Friday, August 5th. Jefferies Group reaffirmed a “buy” rating on shares of Neurocrine Biosciences in a report on Wednesday, June 8th. Robert W. Baird reaffirmed a “buy” rating on shares of Neurocrine Biosciences in a report on Sunday, May 8th. Finally, Leerink Swann reissued an “outperform” rating and set a $63.00 price objective on shares of Neurocrine Biosciences in a report on Wednesday, June 1st. One investment analyst has rated the stock with a sell rating and ten have issued a buy rating to the company’s stock. Neurocrine Biosciences has an average rating of “Buy” and an average price target of $63.90.

The firm’s market capitalization is $4.29 billion. The stock’s 50 day moving average is $49.10 and its 200 day moving average is $44.66.

In other Neurocrine Biosciences news, Director Corinne H. Nevinny sold 5,000 shares of the stock in a transaction dated Monday, August 8th. The shares were sold at an average price of $48.54, for a total transaction of $242,700.00. Following the transaction, the director now directly owns 25,555 shares in the company, valued at approximately $1,240,439.70. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, insider Christopher Flint Obrien sold 12,500 shares of the stock in a transaction dated Monday, August 15th. The stock was sold at an average price of $48.73, for a total transaction of $609,125.00. Following the transaction, the insider now owns 55,044 shares in the company, valued at $2,682,294.12. The disclosure for this sale can be found here.

An institutional investor recently bought a new position in Neurocrine Biosciences stock. I.G. Investment Management LTD. purchased a new position in shares of Neurocrine Biosciences Inc. (NASDAQ:NBIX) during the fourth quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor purchased 45,000 shares of the company’s stock, valued at approximately $2,546,000. I.G. Investment Management LTD. owned approximately 0.05% of Neurocrine Biosciences as of its most recent filing with the SEC.

Neurocrine Biosciences, Inc is engaged in the development of pharmaceutical products focused on neurological and endocrine-based diseases and disorders. The Company’s two lead late-stage clinical programs are Elagolix, a gonadotropin-releasing hormone (GnRH) antagonist for women’s health that is partnered with AbbVie Inc (AbbVie), and NBI-98854 (valbenazine), a vesicular monoamine transporter 2 (VMAT2) inhibitor for the treatment of movement disorders.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.